Distribution of the stay time of the soda cellulose in the ageing apparatus

1972 ◽  
Vol 2 (6) ◽  
pp. 573-574
Author(s):  
O. D. Chanchikova ◽  
T. N. Gavrilets
Keyword(s):  
Soda Cellulose ◽  
Stay Time

An emergency medical process improvement for the reduction of service stay time

2009 ◽  
Vol 10 (1) ◽  
pp. 191-224
Author(s):  
송재호 ◽  
배주억 ◽  
송준우 ◽  
김경섭 ◽  
박유섭 ◽  
...  
Keyword(s):  
Process Improvement ◽  
Emergency Medical ◽  
Stay Time ◽  
Medical Process

scholarly journals A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Anurag Srivastava ◽  
Manickavasagam Rengaraju ◽  
Saurabh Srivastava ◽  
Vimal Narayan ◽  
Vivek Gupta ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
List Type ◽  
Rt Pcr ◽  
Randomized Controlled ◽  
End Of Treatment ◽  
Stay Time ◽  
Full Protocol ◽  
Double Blinded

Abstract Objectives The primary objectives of the study are to determine the effectiveness of the Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy Treatment to compared with Placebo (Decaffeinated Tea) with standard Allopathy Treatment in the management of Symptomatic COVID 19 patients and also in reduction of Hospital Stay Time & Changes in Immunological (IL6) and Bio Chemical Markers (Ferritin, CRP, D-Dimer and LDH). The secondary objectives are to evaluate the safety of the trial medicines and their effects in the reduce the risks of the disease. In addition, to document the profile of Symptomatic COVID 19 patients as per Siddha Principles. Trial Design A Double Blinded, Three arm, Single Centre, Placebo Controlled, Exploratory and comparative Randomized Controlled Trial Participants Patients who were admitted to the COVID Care Centre at Govt. Institute of Medical Sciences. Noida in India will be recruited. These will be patients with Mild and Moderate symptoms with laboratory confirmed COVID 19 (RT – PCR Tested Positive) aged 18-65, willing and consenting to participate. Intervention and comparator Arm I: Decaffeinated Tea (Placebo – similar in taste and appearance to the other Two Decoctions), 60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days. Arm II: Nilavembu Kudineer (The Siddha Medicines which is used as a standard Anti-Viral drug for the past Pandemics by Siddha Physicians) 60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days. Arm III: Kaba Sura Kudineer (The Siddha Medicine which is proposed to be used as a Treatment for COVID 19 based on Siddha Literature) 60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days. The investigational drugs are registered products under the Govt.of India and bought from GMP Certified Manufacturing Units. Main Outcomes Primary outcomes: Reduction in Viral load of SARS-CoV-2 at the end of treatment (10 days). 2. Time taken to convert Patient from symptomatic to Asymptomatic based on Reduction in clinical symptoms (10 days). 3. Effect of drugs inflammatory markers (IL6,) at the end of treatment (10 days). 4. Reduction in hospital stay time (20 days follow up). (Based on RT PCR CT Value 3rd, 6th if needed 10th day). (Based on IL 6 Value needed 10th day or IL6 value on turning negative. (entry level/exit level). Secondary outcomes (10 days): Reduction in use of Intensive Supportive Care. 2. Reduction in incidence of complications (Acute Respiratory Distress Syndrome, other systemic complications). 3. MuLBSTA score for viral pneumonia (multinodular infiltration, hypo-lymphocytosis, bacterial co infection, Total Leucocyte Count (TLC ≤ 0.8 x 109/L), smoking history, hyper-tension and age) score. 4. Laboratory markers (Haematological & Biochemical Markers). 5. Adverse events/effects Siddha-based measurements. 6. Siddha Udaliyal assessment by using Yakkai Ilakkanam (YI) Tool to diagnose body condition for covid-19 patients. Randomisation The assignment of the participants into 3 Groups will be allocated in 1:1:1 Ratio through randomization Blocks in Microsoft Excel by a Statistician who is not involved in the study. The allocation scheme will be made by another statistician by using a closed envelope after the assessment of eligibility and Informed consent procedures. The groups will be balanced for age and sex with 3:1 Ratio in each group for mild: severe COVID-19 symptoms. Blinding The Study is Double Blinded. Participants and Investigators were blinded. Numbers to be randomized (Sample size) Sample size could not be calculated, Since there are no prior trials on KSK and NVK as a comparative trial. In addition, there are no prior trials on KSK and NVK in this region. A total Number of 120 Patients, 40 each in 3 groups will be recruited in 1:1:1 Ratio. Trial Status Protocol Number : SCRUND GIMS Noida Study 1,Version: 2.0 Protocol Date : 20.08.2020 The recruitment period is completed for the trial. The Trial started its recruitment on 22.8.2020. We anticipate study including data analysis will finish in January 2021. This is to state that it was a late submission from authors for publication of the protocol to the BMC, after enrolment in the study was over. Trial Registration The trial protocol was registered with CTRI (Clinical Trial Registry of India) and number is CTRI/2020/08/027286 on 21.08.2020 Full Protocol The full Protocol is attached as an additional file, Accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated. This letter serves as a summary of the key elements of the full protocol. The Study protocol has been reported in accordance with the SPIRIT guidelines.

THE SIMULATION MODELLING METHODS FOR ORGANIZATION OF THE ONCOLOGY PATIENTS ROUTING

2021 ◽  
Author(s):  
Julya Zuenkova ◽  
◽  
Dmitry Kicha
Keyword(s):  
Waiting Time ◽  
Simulation Modeling ◽  
Simulation Modelling ◽  
X Ray ◽  
Modeling Methods ◽  
Care Services ◽  
Stay Time ◽  
Therapy Room ◽  
Oncology Care ◽  
Modelling Methods

Patient routing is a key tool for ensuring the availability and quality of cancer care, ensuring early detection of pathology and timely treatment. Mathematical and simulation modeling methods allow to predict the bottlenecks of patient flows and plan the optimal distribution of healthcare resources. Goal to optimize patients’ pathways for oncology care using the simulation modelling methods. Materials and methods Patient routing was presented in the logic of discrete events, the average resource utilization, the patient’s stay time were described, the bottlenecks of the system were determined. Simulation modeling methods were used to build the optimal organization of oncology care services in the region. Results The average waiting time at the pre-hospital stage was 10 days, the average hospitalization time for X-ray therapy was 24 bed days, the throughput of the X-ray therapy room was 6 patients per week, the average duration of the X-ray therapy session per patient was 10 minutes. With the help of simulation modeling methods, a multimodal system of oncodermatology care was created and put into practice, which allowed to reduce the patient’s waiting time for treatment to 0.7 days, increasing the throughput of the entire system.

scholarly journals Analysis of Factors Related to Length of Stay Time in Patients with Back Pain at Emergency Department

2017 ◽  
Vol 30 (4) ◽  
pp. 173-178
Author(s):  
Kwang Yong Choi ◽  
Byung Hak So ◽  
Hyung Min Kim ◽  
Kyung Man Cha ◽  
Won Jung Jeong
Keyword(s):  
Emergency Department ◽  
Back Pain ◽  
Length Of Stay ◽  
Stay Time

scholarly journals Study of outcome of knee joint in patients with fracture distal femur versus fracture ipsilateral femur and tibia

2021 ◽  
Vol 12 (2) ◽  
pp. 1174-1181
Author(s):  
Ravindra B Gunaki ◽  
Chitresh Mehta ◽  
Rahul Sharma ◽  
Swapnil Chitnavis
Keyword(s):  
Knee Joint ◽  
Distal Femur ◽  
Weight Bearing ◽  
Early Mobilization ◽  
Bony Union ◽  
Fracture Femur ◽  
Articular Fractures ◽  
Stay Time ◽  
A Prospective Study ◽  
Type Of Fracture

The posture on the two wheeler at the speed we travel, makes knee the vulnerable joint of all in any of the mishaps. We as orthopedic surgeons see the fractures around the knee joint as one of the most studied concept in the subject. This is a prospective study conducted, over 2 years, in Krishna Institute of Medical Sciences, Deemed to be University, Karad. In this study, 20 cases of fracture distal femur and 20 cases of ipsilateral fracture femur and tibia were studied to evaluate outcome of knee joint and post surgical stabilization of fractures. The fractured limb was stabilized with splinting the limb in Thomas splint or plaster slab. The type of fracture, type of fracture fixation, duration of hospital stay, time of union and time to start weight bearing are evaluated. According to Neer’s score, Good outcome was found in both Fracture Distal femur and Ipsilateral Fracture Femur and tibia. The functional outcome was found to be better in diaphyseal fractures femur and tibia treated with intramedullary interlock nailing which allowed early mobilization and weight bearing than in intra-articular fractures treated with plating. Bony union occurred early in closed, diaphyseal and simple transverse or oblique fractures and delayed in open, intraarticular and comminuted fractures. 

Effect of Growth Hormone on Outcome of Pediatric Burn Patients

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Gihan Seif El Nasr Mohamed ◽  
Salwa Omar ElKhattab Amin ◽  
Mohamed Mohamed Kamal ◽  
Sherif Hany Adly Loka
Keyword(s):  
Growth Hormone ◽  
Conventional Treatment ◽  
Control Group ◽  
P Value ◽  
Time Interval ◽  
Burn Patients ◽  
Icu Stay ◽  
Co Morbidity ◽  
Stay Time ◽  
Inhalational Injury

Abstract Background A burn is a thermal injury caused by biological, chemical, electrical and physical agents with local and systemic repercussions. There are several ways of classifying burns: Classification by mechanism or cause, Classification by the degree and depth of a burn, Classification by extent of burn the extent of burn. Objectives The objective of this study was to determine the safety and efficacy of using recombinant human growth hormone (rhGH) in the treatment of pediatric burn victims and their ICU length of stay, mortality and morbidity. Patients and Methods This study was an Interventional randomized controlled Double Blind Study in which Patients subdivided randomly into 2 groups: Group A received somatotropine hormone after their 3 days of resuscitation besides their conventional treatment during their stay in the Burn ICU. Group B received the conventional treatment only in the Burn ICU. Results The comparison between the GH group and the control group showed that the mean ICU stay in days in GH group was 10.88 while in the control group 13.59 with P value 0.018 as a significant result as the GH group showed a less ICU stay time than the control group with approximately 20%. Mortality in the GH group was 6.2% from the total number of the group while in control group 18.8% from the total number of the group with P value 0.033 as a significant result yet the mortality may also depend on other factors as the degree of burn and the area of burn and the associated events like inhalational injury or delay post burn or any other co-morbidity. Morbidity results seen was 0% in control group and 4.7% in GH group with P value 0.080 as a non-significant result, morbidity was in the form of hyperglycemia. Conclusion The use of recombinant Growth hormone with a dose of 0.2 mg/Kg SQ 2 days per week with 3 days time interval in pediatric burn patients after their primary resuscitation from the burn injury, shows a marvelous improvement concerning the ICU stay time as the patient received the growth hormone showed an approximately 20% time less ICU stay than the control group this may be accounted for the faster wound healing and readiness for grafting and even faster graft healing, also a decreased mortality in a significant way, although mortality may depend on many factors in burn patients like degree of burn and the area of burn and the associated events like inhalational injury or any other co-morbidity.

Sign in / Sign up

Export Citation Format

Share Document